中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 9
Sep.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(9): 2040-2045

Effect of Yangxue Rougan pills on the TGF-β1/Smad signaling pathway in a rat model of liver fibrosis induced by multiple factors

DOI: 10.3969/j.issn.1001-5256.2022.09.018
  • 1.

    Department of Clinical Pharmacy, Baoji Hospital of Traditional Chinese Medicine, Baoji, Shaanxi 721000, China

  • 2.

    Tsinghua Deren Xi'an Happiness Pharmaceutical Co., Ltd., Xi'an 710043, China

  • 3.

    Institute of Traditional Chinese Medicine, Shaanxi Academy of Traditional Chinese Medicine, Xi'an 710003, China

Research funding:

Science and Technology Plan of Shaanxi Province-Key Industry Chain Project (2020ZDLSF05-06)

More Information
  • Corresponding author: ZHANG Xiaoli, 380136809@qq.com(ORCID: 0000-0003-2405-5244)
  • Received Date: 2022-04-24
  • Accepted Date: 2022-05-30
  • Published Date: 2022-09-20
    Abstract
  •   Objective  To investigate the effect of Yangxue Rougan pills on a rat model of liver fibrosis induced by multiple factors and the mechanism of action of Yangxue Rougan pills in the treatment of liver fibrosis.  Methods  A total of 50 male rats were randomly divided into blank control group, multi-factor model group, Fuzheng Huayu capsule group, and high-, middle-, and low-dose Yangxue Rougan pill groups. The rats in the blank control group were given normal water and feed, and those in the other groups were given modified high-fat low-protein diet and 5% alcohol, as well as subcutaneous injection of olive oil solution containing 40% carbon tetrachloride and intraperitoneal injection of pig serum 0.5 mL per rat, twice a week for 12 consecutive weeks. Since week 7, the rats in the high-, middle-, and low-dose Yangxue Rougan pill groups were given Yangxue Rougan pills at a dose of 9.5, 4.75, and 2.38 g/kg, respectively, those in the Fuzheng Huayu capsule group were given Fuzheng Huayu capsules at a dose of 0.75 g/kg, and those in the blank control group and the multi-factor model group were given an equal volume of distilled water by gavage every day for 6 consecutive weeks. The rats were treated at week 12. HE staining and Masson staining were used to observe the degree of liver fibrosis in rats, and PCR and Western blot were used to measure the expression of TGF-β1, Smad3, and Smad7 in the liver. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the Dunnett's t-test was used for further comparison between two groups.  Results  Compared with the blank control group, the multi-factor model group had a severely damaged lobular structure and a significantly higher degree of liver fibrosis, with the formation of pseudolobules with different sizes; compared with the multi-factor model group, the Yangxue Rougan pill groups had a significant improvement in the degree of liver fibrosis, with the most significant therapeutic effect in the high- and middle-dose Yangxue Rougan pill groups. Compared with the blank control group, the multi-factor model group had significant increases in the expression of TGF-β1 and Smad3 and a significant reduction in the expression of Smad7 in liver tissue (all P < 0.05); compared with the multi-factor model group, the Yangxue Rougan pill groups had a significant reduction in the expression of TGF-β1 and a significant increase in the expression of Smad7 (all P < 0.05); compared with the multi-factor model group, the high- and middle-dose Yangxue Rougan pill groups had a significant reduction in the expression of Smad3 (both P < 0.05).  Conclusion  Yangxue Rougan pills can significantly inhibit liver fibrosis in rats by downregulating the expression of TGF-β1 and Smad3 and upregulating the expression of Smad7, and therefore, the TGF-β1/Smad signaling pathway is one of the mechanisms of action of Yangxue Rougan pills in improving liver fibrosis.

     

    • FullText(HTML)
  • loading
    • References(11)
  • [1]
    DONGIOVANNI P, ROMEO S, VALENTI L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors[J]. World J Gastroenterol, 2014, 20(36): 12945-12955. DOI: 10.3748/wjg.v20.i36.12945.
    [2]
    LEE JH, JANG EJ, SEO HL, et al. Sauchinone attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway[J]. Chem Biol Interact, 2014, 224: 58-67. DOI: 10.1016/j.cbi.2014.10.005.
    [3]
    HAMZAVI J, EHNERT S, GODOY P, et al. Disruption of the Smad7 gene enhances CCI4-dependent liver damage and fibrogenesis in mice[J]. J Cell Mol Med, 2008, 12(5B): 2130-2144. DOI: 10.1111/j.1582-4934.2008.00262.x.
    [4]
    ATTA HM. Reversibility and heritability of liver fibrosis: Implications for research and therapy[J]. World J Gastroenterol, 2015, 21(17): 5138-5148. DOI: 10.3748/wjg.v21.i17.5138.
    [5]
    ELPEK GÖ. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update[J]. World J Gastroenterol, 2014, 20(23): 7260-7276. DOI: 10.3748/wjg.v20.i23.7260.
    [6]
    OAKLEY F, MESO M, IREDALE JP, et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis[J]. Gastroenterology, 2005, 128(1): 108-120. DOI: 10.1128/CVI.00541-10.
    [7]
    DOOLEY S, TEN DIJKE P. TGF-β in progression of liver disease[J]. Cell Tissue Res, 2012, 347(1): 245-256. DOI: 10.1007/s00441-011-1246-y.
    [8]
    YANG AT, LI WY, YAN XZ, et al. Hepcidin decreased hepatic stellate cells activation[J]. J Clin Exp Med, 2020, 19(10): 1037-1040. DOI: 10.3969/j.issn.1671-4695.2020.010.009.

    杨爱婷, 李为雨, 严旭禛, 等. 铁调素在肝纤维化中的表达特点及对肝星状细胞的作用[J]. 临床和实验医学杂志, 2020, 19(10): 1037-1040. DOI: 10.3969/j.issn.1671-4695.2020.010.009.
    [9]
    CUI W, JIN HB, LI ZW. Mechanism of the transforming growth factor-beta induction of fibronectin expression in hepatic stem-like cells[J]. Braz J Med Biol Res, 2010, 43(1): 36-42. DOI: 10.1002/hep.23354.
    [10]
    LATELLA G, VETUSCHI A, SFERRA R, et al. Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice[J]. Liver Int, 2009, 29(7): 997-1009. DOI: 10.1111/j.1478-3231.2009.02011.x.
    [11]
    YANG XY, YANG Y, ZHENG Y, et al. Effect of exogenous Smad7 gene transfected hepatic stellate cells on mRNA expression of transforming growth factor beta 1, collagen Ⅰ and collagen Ⅲ [J]. J Clin Rehabil Tissue Eng Res, 2009, 13(50): 9887-9891. DOI: 10.3969/j.issn.1673-8225.2009.50.018.

    杨小艳, 杨勇, 郑勇, 等. 外源Smad7转染肝星状细胞及对转化生长因子β1和Ⅰ、Ⅲ型胶原mRNA表达的影响[J]. 中国组织工程研究与临床康复, 2009, 13(50): 9887-9891. DOI: 10.3969/j.issn.1673-8225.2009.50.018.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (469) PDF downloads(29) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return